Welcome to our dedicated page for Solesence SEC filings (Ticker: SLSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solésence, Inc. (Nasdaq: SLSN) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a scientifically driven health care solutions company in beauty and life science categories. These SEC filings cover its activities in mineral-based skin care, sun care and color cosmetics, as well as its broader corporate and financial structure.
On this page, investors can review Solésence’s periodic reports, such as its Form 10-K referenced in company press releases, which describe risk factors, dependence on key customers, intellectual property around engineered materials and technologies, and other aspects of its household and personal products business. Quarterly results are often accompanied by Form 8-K filings under Item 2.02, in which Solésence furnishes earnings press releases detailing revenue composition, gross profit, operating expenses and non-GAAP metrics.
Additional Form 8-K filings document material events, including leadership transitions, employment agreements with senior executives, settlements related to commercial disputes, and outcomes of the annual meeting of stockholders. Proxy materials such as the DEF 14A provide information on the company’s classified board, equity compensation plan approvals and auditor ratification, as well as voting results.
Through Stock Titan, users can access these Solésence filings as they are made available on EDGAR and use AI-powered summaries to interpret lengthy documents. The platform can highlight key points from 10-K and 10-Q reports, explain the implications of 8-K items, and surface information related to executive arrangements and shareholder approvals. Filings related to equity compensation, board structure and customer or financing arrangements are particularly relevant for understanding Solésence’s governance and its position within the consumer defensive sector.
Solésence, Inc. reported a net loss for the quarter ended March 31, 2026 as revenue declined. Total revenue was $12,957 (in thousands), down from $14,625 (in thousands) a year earlier, driven by lower consumer products and advanced materials sales, partly offset by higher personal care ingredients revenue.
Gross profit was $3,337 (in thousands), roughly flat versus $3,382 (in thousands), but higher selling, general and administrative expenses of $2,799 (in thousands) and research and development of $1,042 (in thousands) contributed to a net loss of $766 (in thousands), compared with net income of $80 (in thousands) in 2025.
Operating cash flow improved to $1,517 (in thousands) from a use of $7,221 (in thousands), aided by working capital changes. Cash decreased to $573 (in thousands) as of March 31, 2026, while related-party borrowings remained significant, including a $9,500 (in thousands) inventory facility and $3,047 (in thousands) drawn on an accounts receivable line.
Solésence, Inc. reported first quarter 2026 revenue of $13.0 million, down from $14.6 million a year earlier, as it invested in its Transform and Transcend operational initiative. Despite lower sales, gross profit was $3.3 million and gross margin improved to 26% from 23%.
The company posted a net loss of approximately $0.8 million for the quarter, compared with net income of about $0.08 million in 2025, and Adjusted EBITDA declined to $(0.1) million from $0.6 million. Management highlighted near-term profitability pressure from training and organizational restructuring, but expects efficiency gains and lower labor costs to support better results later in the year.
Solésence, Inc. announced that its Board of Directors appointed Marc James as a Class II independent director, effective April 24, 2026. He will serve for the remainder of the Class II term, ending at the 2026 Annual Meeting of Shareholders.
James joins the Board’s Audit and Finance, Compensation, and Nominating and Corporate Governance Committees. The company highlights his capital markets and strategic experience as support for its Transform & Transcend strategic initiative and long-term growth objectives.
Solésence, Inc. filed Amendment No. 1 to its annual report to add Exhibit 97.1, which was inadvertently omitted from the original filing. The company states that no other items are being revised and the amendment does not reflect events after the original report.
The aggregate market value of voting stock held by non‑affiliates was $27,254,231 as of June 30, 2025, and 70,632,445 common shares were outstanding as of March 30, 2026. The filing also lists numerous previously filed material contracts, loan agreements, employment agreements, and the Solésence 2025 Equity Compensation Plan as exhibits.
Solésence, Inc. reports strong 2025 growth as it advances its rebranding from Nanophase Technologies into a skin-health focused consumer products company. Total revenue rose to $62,064, driven mainly by prestige beauty consumer products built on its Active Stress Defense™ technology and mineral-based UV protection APIs.
The company increasingly prioritizes finished “white label” and custom skin-care products over legacy advanced materials, operates two FDA-registered, ISO-certified facilities near Chicago, and invests heavily in R&D and capacity to meet what management describes as unprecedented demand from brand partners.
Solésence, Inc. reported record full-year 2025 revenue of $62.1 million, up 19% from $52.3 million, as it expanded its SPF-infused beauty product portfolio. Despite higher sales, full-year gross margin fell to 26% from 31% and net income declined to $1.8 million from $4.2 million, reflecting higher operating costs.
In the fourth quarter, revenue was $12.5 million, roughly flat year over year, but gross margin improved to 27% from 22%, turning a net loss of $0.6 million in 2024’s quarter into net income of $0.2 million. The company highlighted its “Transform & Transcend” initiative, aimed at operational excellence, technology-driven market expansion, service model innovation, and global growth with brand partners, alongside adding 20 new brand partners and securing 16 new patents.
Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer. Under the agreement, effective December 2, 2025, Jankowski will receive severance pay totaling $366,912, accelerated vesting of all his outstanding stock options, and continued company-paid health insurance premiums under COBRA for the duration of the severance period. In return, he is providing a broad release of claims against the company and reaffirming obligations such as restrictive covenants and assistance in certain potential disputes. The separation agreement is filed as an exhibit to this report, with some portions redacted as confidential.
Solésence, Inc. filed a Form 8‑K to furnish information under Item 2.02 (Results of Operations and Financial Condition). The company reported that it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference.
The filing also includes a “Solésence Third Quarter 2025 Conference Call Script” as Exhibit 99.2. These materials provide the company’s communications around its quarterly results, with the exhibits serving as the official source documents.
Solésence, Inc. reported Q3 2025 results with total revenue of $14,597, down from $16,866 a year ago, and a net loss of $1,120 versus prior-year income of $3,045. Gross profit was $3,370 compared with $6,102 as cost of revenue rose to $11,227. Selling, general and administrative expense increased to $3,069, reflecting higher legal, credit loss allowance, employee and NASDAQ uplisting costs.
For the nine months, revenue reached $49,581, up from $39,780, and net income was $1,627 versus $4,793. Cash was $429 at quarter end, with operating cash outflow of $10,386 and financing inflows of $11,099, including related-party credit facilities. Accounts receivable, net, increased to $9,709 and the allowance for credit losses to $1,729. Three customers represented 60% of Q3 revenue.
Other items included recognition of $1,234 from the Employee Retention Credit and $194 of related interest. A confidential settlement provides for a $675 payment to Solésence by January 15, 2026. The company also notes BASF supply agreement contingencies that could impact equipment and revenue if triggered.
Solésence, Inc. entered a settlement agreement with Solarium Brands, LLC and A-Frame Brands, LLC to resolve disputes related to previously sold consumer care products. Under the agreement, Solarium will make a one-time settlement payment of $675,000 to Solésence on or before January 15, 2026.
The agreement finalizes a commercial dispute and provides for a defined payment to Solésence. The full agreement was filed with certain confidential portions redacted.